Clinical Trial

Adiposity and Endothelin Receptor Function

Study acronym: END-RF
Active, Not Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 6, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
Elevated levels of ET-1 have been implicated in cardiovascular disease and some forms of hypertension. Due to the strong, positive correlation between obesity and hypertension, the present study will explore the contribution of adiposity in ETB receptor function and aim to elucidate if ETB receptor dysfunction is a major contributor to hypertension in obesity.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2018-07-10; most recent amendment 2025-02-05.
Status change: Recruiting → Active, Not Recruiting 2022-07-18
Trial Details
NCT Number NCT03583866
Lead Sponsor Augusta University
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions Hypertension
Enrollment 25 participants
Start Date 2018-05-21
Primary Completion 2025-12 (estimated)
Study Completion 2026-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-06